



Viral Epidemiology Snapshot: October 30-November 5, 2022

Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV

Virus	#Tested	#Positive	% Positive
Flu A	877	141	16.1%
Flu B	877	5	0.6%
RSV	650	308	47.4%
CoV-2 Diagnostic	1097	54	4.9%
CoV-2 Screening	15	2	13.3%


Other Respiratory Viruses

Virus	#Tested	#Positive	% Positive
Adenovirus	535	32	6.0%
Coronavirus 229E	535	1	0.2%
Coronavirus HKU1	535	2	0.4%
Coronavirus NL63	535	1	0.2%
Coronavirus OC43	535	0	0.0%
Metapneumovirus	535	10	1.9%
Rhinovirus/Enterovirus	535	149	27.9%
Parainfluenza 1	535	28	5.2%
Parainfluenza 2	535	0	0.0%
Parainfluenza 3	535	10	1.9%
Parainfluenza 4	535	10	1.9%

Flu A Subtyping

2009 H1N1	5
Seasonal H1	2
Seasonal H3	41
No Subtype	93
Pending subtype	0

Flu, RSV, & CoV-2 Trends




This report contains results for molecular and antigen tests ordered throughout the CHMCA network and performed at the Akron/Mahoning Valley laboratories. It also includes Point-of-Care tests (POCT) for influenza and SARS-CoV-2 (as of 2/2020) performed at ACHP locations.

Notes on Influenza A subtyping: Influenza A found by the Respiratory Film Array test will also include a subtype. Influenza A found by POCT methods will be listed as “no subtype”.

Notes on SARS-CoV-2 data: In the top chart, the red CoV-2 line traces the total number of patients testing positive each week. In the bottom chart, the orange line (“Diagnostic”) shows data for all patients with symptoms or known exposures while the purple line (“Screening”) shows data for undergoing pre-procedure screening.

CoV-2 Positivity Rate Trends



As of 10/2021, the screening line shows patients who have been designated as “pre-procedure” in their testing order questionnaire, as well as participants in the employee screening program. In 9/2022 the employee screening program ended and pre-procedure screening was made at provider-discretion.

